Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. develops the investigational Aethlon Hemopurifier, an extracorporeal therapeutic device for oncology and other indications. Company news centers on clinical-stage development in solid tumors and infectious-disease applications, including safety, feasibility and dose-finding work for Hemopurifier treatments used alongside anti-PD-1 therapies such as pembrolizumab or nivolumab.
Recurring updates also address preclinical research on the device's GNA affinity resin, extracellular vesicle removal and inflammatory microRNAs, along with quarterly financial results, corporate updates and investor presentations. The company's disclosures describe a platform designed to selectively remove circulating pathogenic targets from biologic fluids.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced it will release its financial results for Q4 FY2020 on June 25, 2020, at 4:15 PM Eastern Time. A conference call is scheduled for the same day at 4:30 PM Eastern, where management will review results and corporate developments, followed by a Q&A session. The Hemopurifier®, Aethlon's immunotherapeutic device, has received FDA's Breakthrough Device designations for cancer and viral infections, aiming to address critical unmet needs in global health.